Orazipone: Agent for inflammatory bowel disease cytokine modulator

Drugs of the Future

Volumn 23, Issue 1, 1998, Pages 28-31

  Wrobleski, T ^a   Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2,6 DI TERT BUTYL 4 [(ETHYLAMINO)METHYL]PHENOL; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 8; LEXIPAFANT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NICOTINE; OLSALAZINE; ORAZIPONE; PREDNISONE; RIFAXIMIN; SALAZOSULFAPYRIDINE; SAREDUTANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RECTAL DRUG ADMINISTRATION;

EID: 0031888732     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.01.441671     Document Type: Article

References (12)

1. Backstrom, R.J., Honkanen, E.J., Pystynen, J.J. et al. (Orion Yhtymä Oy). Substd. β-diketones and their use. EP 440324, JP 92253933, US 5185370.
2. Rask-Madsen, J. Soluble mediators and the interaction of drugs in IBD. Med Actual/Drugs Today 1998, 34: 45-63.
3. Stein, R.B., Hanauer, S.B. Medicinal management of Crohn's disease. Med Actual/Drugs Today 1998, 34: in preparation.
4. Brynskov, J. Therapeutic options for patients with inflammatory bowel disease: New steroids. Med Actual/Drugs Today 1997, 33: 131-8.
5. Brynskov, J. Therapeutic options for patients with inflammatory bowel disease: Thiopurine immunosuppressants. Med Actual/Drugs Today 1997, 33: 413-9.
6. Egan, L.J., Sandborn, W.J. Drug therapy of inflammatory bowel disease. Med Actual/Drugs Today 1998, 34: in preparation.
7. Nissinen, E., Serkkola, E., Penttilä, K.E., Kaivola, J., Aho, P., Lindén, I.-B. Suppression of cytokine production and neutrophil activation by an immunomodulating agent OR-1384. Dig Dis Week (May 10-16, Washington DC) 1997, Abst 2889.
8. Murthy, S., Murthy, N.S., Coppola, D., Aho, P., Linden, I.-B. A novel immunomodulating agent (OR-1384) ameliorates inflammation and tissue damage in dextran sulfate (DSS) model of mouse colitis. Dig Dis Week (May 10-16, Washington DC) 1997, Abst 4413.
9. Murthy, S., Murthy, N.S., Aho, P., Linden, I.-B. A novel immunomodulating agent (OR-1384) ameliorates inflammation and tissue damage in dextran sulfate (DSS) model of mouse colitis. Inflamm Res 1997, 46(Suppl. 3): Abst P-I-3-29.
10. Aho, P., Koponen, A., Haasio, K., Lindén, I.-B. OR-1384, a novel locally acting immunomodulating agent, protects against experimental colitis. Dig Dis Week (May 10-16, Washington DC) 1997, Abst 4339.
11. Ranta-Knuuttila, T., Kiviluoto, T., Kärkkäinen, P., Kivilaakso, E. The novel thiol modulating agent, OR-1384, protects rat gastric mucosa against ethanol and aspirin (ASA) induced injury. Dig Dis Week (May 10-16, Washington DC) 1997, Abst 3679.
12. Product development status. Orion Pharma Company Communication 1997, December 1.